Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014 by Fleming, S., Yannakou, C. K., Haeusler, G. M., Clark, J., Grigg, A., Heath, C. H., Bajel, A., van Hal, S. J., Chen, S. C., Milliken, S. T., Morrissey, C. O., Tam, C. S., Szer, J., Weinkove, R., Slavin, M. A.

Get full text

Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION... by Minson, A., Verner, E., Giri, P., Wong, S. M., Ratnasingam, S., Butler, J., Janowski, W., Ku, M., Cheah, C. Y., Hertzberg, M., Herbert, K., Hamad, N., Yannakou, C. K., Neeson, P., Saghebi, J., Blombery, P., Robertson, M., Lau, L. S., Xie, J., Seymour, J. F., Dickinson, M.

Get full text

TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIES by Cheah, C. Y, Jurczak, W, Lasica, M, Wickham, N, Wróbel, T, Walewski, J, Yannakou, C. K, Cheung, S, Lewis, K. L, Długosz‐Danecka, M, Giannopoulos, K, Miskin, H. P, Tang, J.‐P, Normant, E, O'Connor, O. A, Ricart, A. D, Tam, C. S

Get full text

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia by Cummins, K D, Jane, S M, Ninkovic, S, Bazargan, A, Filshie, R, Sutrave, G, Hertzberg, M, Scott, A, Lane, S, Yannakou, C K, Ritchie, D, D'Rozario, J, Black, J, Bavishi, K, Wei, A

Get full text

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia by Cummins, K D, Jane, S M, Ninkovic, S, Bazargan, A, Filshie, R, Sutrave, G, Hertzberg, M, Scott, A, Lane, S, Yannakou, C K, Ritchie, D, D'rozario, J, Black, J, Bavishi, K, Wei, A

Get full text

Erratum: Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia by Cummins, K D, Jane, S M, Ninkovic, S, Bazargan, A, Filshie, R, Sutrave, G, Hertzberg, M, Scott, A, Lane, S, Yannakou, C K, Ritchie, D, D'Rozario, J, Black, J, Bavishi, K, Wei, A

Get full text

Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy by Fox, Lucy C, Yannakou, Costas K, Ryland, Georgina, Lade, Stephen, Dickinson, Michael, Campbell, Belinda A, Prince, Henry Miles

Get full text

Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021 by Teh, Benjamin W., Yeoh, Daniel K., Haeusler, Gabrielle M., Yannakou, Costas K., Fleming, Shaun, Lindsay, Julian, Slavin, Monica A.

Get full text

Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial by Ailawadhi, Sikander, Chen, Zi, Huang, Bo, Paulus, Aneel, Collins, Mary C, Fu, Lei Tommy, Li, Mingyu, Ahmad, Mohammad, Men, Lichuang, Wang, Hengbang, Davids, Matthew S, Liang, Eric, Mekala, Divya J, He, Zhicong, Lasica, Masa, Yannakou, Costas K, Parrondo, Ricardo, Glass, Laura, Yang, Dajun, Chanan-Khan, Asher, Zhai, Yifan

Get full text

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas by Song, Yuqin, Ding, Ning, Yoon, Dok Hyun, Reneau, John C., Wilcox, Ryan A., Kim, Won Seog, Kim, Youn H., Khodadoust, Michael S., Feldman, Tatyana A., Yannakou, Costas K., Giri, Pratyush, Brammer, Jonathan E, Hsu, Lih-Yun, Yuan, Hongwei, Verner, Erik, Mahabhashyam, Suresh, Miller, Richard A.

Get full text

Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy by Fox, Lucy C, Yannakou, Costas K, Ryland, Georgina, Lade, Stephen, Dickinson, Michael, Campbell, Belinda A, Prince, Henry Miles

Get full text